T1	Participants 1144 1267	intent-to-treat (ITT) and study-completer populations pooled from three randomized, double-blind, placebo-controlled trials
T2	Participants 162 372	among patients receiving topiramate (TPM) 100 mg/d in two divided doses for migraine prevention in three randomized, double-blind, placebo-controlled, 26-week trials with similar protocols and study populations
T3	Participants 2071 2172	ITT (TPM, n = 372; placebo, n = 362) and study-completer (TPM, n = 220; placebo, n = 216) populations
T4	Participants 2451 2492	prevention of migraine headache in adults
T5	Participants 64 80	prevent migraine
